Tirzepatide and Tachycardia: Should a Faster Heart Rate Concern You?

Why does tirzepatide affect heart rate at all?

Tirzepatide activates two receptors involved in appetite regulation and blood-sugar control — GIP and GLP-1. GLP-1 receptors are also present in the heart and the blood vessels, which is why medicines that act on this pathway can produce small cardiovascular effects alongside their metabolic ones. The most commonly reported one is a modest rise in resting pulse. In the SURMOUNT-1 trial, participants saw mean increases of roughly 2–3 beats per minute compared with placebo, a finding consistent across the wider tirzepatide evidence base. For context, a resting heart rate between 60 and 100 beats per minute is considered normal in adults; a few extra beats at the lower end of that range rarely causes symptoms and is not in itself dangerous for most people.

The effect is more pronounced at higher doses and more noticeable at transitions, so the period just after a dose increase is the one most people describe noticing a flutter or an awareness of their heartbeat. The stepped dosing schedule (starting at 2.5 mg and moving upward gradually) partly exists to allow the body to adjust, and if you are curious about what reaching tirzepatide 30 mg involves, our dedicated page explains how that ceiling dose is approached and what to expect. You can read a full overview of how the medicine works on our tirzepatide information page.

When a faster pulse is worth monitoring and when to get help

The decision most people are actually facing is this: my heart rate has gone up a little, do I carry on, call someone, or stop? The NHS guidance on tirzepatide lists heart palpitations and a fast heartbeat among the side effects to be aware of, and the clinical distinction matters here.

A mild rise that causes no symptoms and settles within a few weeks is generally managed by watching and waiting. A heart rate that stays persistently above 100 beats per minute at rest (a state known as tachycardia) is something to raise with your prescriber at your next contact, or sooner if it is accompanied by dizziness, breathlessness, chest pain, or fainting. Those combinations are not expected side effects of tirzepatide and need medical assessment without delay. The same applies if you experience a heart rhythm that feels irregular rather than simply fast.

You can report unexpected side effects directly to the MHRA using the Yellow Card scheme, which helps regulators monitor medicines in real-world use. Tirzepatide carries a Black Triangle (▼) status, meaning any new safety signals are monitored with extra care. If you have a pre-existing heart rhythm condition such as atrial fibrillation or SVT, that history should be declared fully at the consultation stage, it shapes whether this treatment is right for you, and at what dose.

How this sits in the broader picture of tirzepatide and heart health

It is worth understanding that tirzepatide's relationship with the heart is not straightforwardly harmful. Obesity itself raises cardiovascular risk, and sustained weight loss of the kind seen in clinical trials generally improves blood pressure, cholesterol, inflammatory markers and, over time, overall heart health. The rise in resting heart rate seen with tirzepatide is a pharmacological effect of the drug itself; the cardiovascular benefits that accumulate over months of treatment tend to move in the opposite direction.

For people comparing their options, our Mounjaro treatment page covers the licensed indications in the UK, and if you are weighing up whether to choose Mounjaro or tirzepatide, our comparison page sets out the practical differences to help you decide. Those considering the cost implications of starting treatment will find honest context on the Mounjaro cost page, which covers what a private prescription typically includes. It is also worth knowing that this is a prescription-only medicine (not something that can be obtained without a clinical assessment) and the prescriber review is where individual cardiac history is taken into account.

Making a decision: what to bring to your consultation

If you are deciding whether to start tirzepatide, or whether to continue after noticing your heart rate has changed, the consultation is where that decision gets made properly. A GPhC-registered prescriber, not an automated system, reads your medical history and weighs it. The questions worth having ready: your resting heart rate before treatment started if you know it, any cardiac diagnoses, any medicines you take that also affect heart rate (beta-blockers and stimulants both interact), and a description of exactly what you noticed, when it started, how long it lasted, whether it came with other symptoms. If you want background on the tirzepatide l formulation before your appointment, our page covers the details worth knowing.

Our clinical team is available to discuss concerns like this, and you can find answers to common questions on our FAQs page. If something feels urgent, the right place is always your GP or 111, not an online pharmacy. For everything else (understanding your options, checking whether this treatment suits your circumstances) starting a free consultation puts your details in front of a prescriber the same day.